ZVSA
ZyVersa Therapeutics, Inc.
Biotechnology
Market Cap$1.58B
5Y Perf.-100.0%
Build Your Comparison
Side-by-side financial analysisZVSA
ALDX
Try popular comparisons:
Stock Comparison
ZVSA vs ALDX
Revenue, margins, valuation, and 5-year total return — side by side.
ALDX
Aldeyra Therapeutics, Inc.
Biotechnology
Market Cap$106M
5Y Perf.-56.4%
ZVSA vs ALDX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ZVSA |  ALDX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.58B | $106M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-1.82B | $-27M |
| Total Debt | $0.00 | $16M |
| Cash & Equiv. | $102M | $70M |
ZVSA vs ALDX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ZVSA
ALDX
| Stock | Feb 22 | Jun 26 | Return |
|---|---|---|---|
| ZyVersa Therapeutic… (ZVSA) | 100 | 0.0 | -100.0% |
| Aldeyra Therapeutic… (ALDX) | 100 | 43.6 | -56.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ZVSA vs ALDX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALDX leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. ZyVersa Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ALDX emerged as the overall leader. Track its performance:
ZVSA
ZyVersa Therapeutics, Inc.
The Income Pick
ZVSA is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.29
- Rev growth -100.0%, EPS growth 50.7%
- Lower volatility, beta 0.29, current ratio 0.03x
Best for: income & stability and growth exposure
ALDX
Aldeyra Therapeutics, Inc.
The Long-Run Compounder
ALDX carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -69.4% 10Y total return vs ZVSA's -100.0%
- 52.8% revenue growth vs ZVSA's -100.0%
- 2.0% margin vs ZVSA's -0.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ALDX | 52.8% revenue growth vs ZVSA's -100.0% |
| Quality / Margins | ALDX | 2.0% margin vs ZVSA's -0.1% |
| Stability / Safety |  ZVSA | Beta 0.29 vs ALDX's 1.36 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ALDX | -39.9% vs ZVSA's -73.2% |
| Efficiency (ROA) | ALDX | -0.0% ROA vs ZVSA's -6.5% |
ZVSA vs ALDX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLZVSALAGGINGALDX
ALDXAldeyra Therapeutics,…
2leads
ZVSAZyVersa Therapeutics,…
2leads
6 Total Categories
CATEGORYLEADERvs ALDXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ZVSA1/1
Valuation MetricsMultiples, price ratios, and targets
ALDX1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ZVSA3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
ALDX5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ZVSA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ZVSA and ALDX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | ZVSAZyVersa Therapeut… | ALDXAldeyra Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$24M | -$28M |
| Net IncomeAfter-tax profit | -$1.8B | -$27M |
| Free Cash FlowCash after capex | -$4.1B | -$26M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +69.9% | +66.4% |
ZVSA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ALDX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ZVSAZyVersa Therapeut… | ALDXAldeyra Therapeut… |
|---|---|---|
| Market CapShares × price | $1.6B | $106M |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $52M |
| Trailing P/EPrice ÷ TTM EPS | -0.05x | -3.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | — | 2.39x |
| Price / FCFMarket cap ÷ FCF | — | — |
ALDX leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
ZVSA leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), ZVSA scores 2/9 vs ALDX's 1/9, reflecting mixed financial health.
| Metric | ZVSAZyVersa Therapeut… | ALDXAldeyra Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | — | -0.0% |
| ROA (TTM)Return on assets | -6.5% | -0.0% |
| ROICReturn on invested capital | — | -2.5% |
| ROCEReturn on capital employed | — | -54.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | — | 0.35x |
| Net DebtTotal debt minus cash | -$102M | -$55M |
| Cash & Equiv.Liquid assets | $102M | $70M |
| Total DebtShort + long-term debt | $0 | $16M |
| Interest CoverageEBIT ÷ Interest expense | -46.26x | -13.78x |
ZVSA leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
ALDX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALDX five years ago would be worth $1,432 today (with dividends reinvested), compared to $1 for ZVSA. Over the past 12 months, ALDX leads with a -39.9% total return vs ZVSA's -73.2%. The 3-year compound annual growth rate (CAGR) favors ALDX at -45.1% vs ZVSA's -88.7% — a key indicator of consistent wealth creation.
| Metric | ZVSAZyVersa Therapeut… | ALDXAldeyra Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | +44.4% | -62.3% |
| 1-Year ReturnPast 12 months | -73.2% | -39.9% |
| 3-Year ReturnCumulative with dividends | -99.9% | -83.4% |
| 5-Year ReturnCumulative with dividends | -100.0% | -85.7% |
| 10-Year ReturnCumulative with dividends | -100.0% | -69.4% |
| CAGR (3Y)Annualised 3-year return | -88.7% | -45.1% |
ALDX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ZVSA and ALDX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ZVSA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than ALDX's 1.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALDX currently trades 28.5% from its 52-week high vs ZVSA's 11.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ZVSAZyVersa Therapeut… | ALDXAldeyra Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.29x | 1.36x |
| 52-Week HighHighest price in past year | $1.67 | $6.18 |
| 52-Week LowLowest price in past year | $0.11 | $1.07 |
| % of 52W HighCurrent price vs 52-week peak | +11.7% | +28.5% |
| RSI (14)Momentum oscillator 0–100 | 44.1 | 49.0 |
| Avg Volume (50D)Average daily shares traded | 5K | 1.2M |
Evenly matched — ZVSA and ALDX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ZVSA as "Buy" and ALDX as "Buy".
| Metric | ZVSAZyVersa Therapeut… | ALDXAldeyra Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $9.67 |
| # AnalystsCovering analysts | 1 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ZVSA leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ALDX leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallZyVersa Therapeutics, Inc. (ZVSA)Leads 2 of 6 categories
Loading custom metrics...
ZVSA vs ALDX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ZVSA or ALDX a better buy right now?
Analysts rate ZyVersa Therapeutics, Inc.
(ZVSA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ZVSA or ALDX?
Over the past 5 years, Aldeyra Therapeutics, Inc.
(ALDX) delivered a total return of -85. 7%, compared to -100. 0% for ZyVersa Therapeutics, Inc. (ZVSA). Over 10 years, the gap is even starker: ALDX returned -69. 4% versus ZVSA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ZVSA or ALDX?
By beta (market sensitivity over 5 years), ZyVersa Therapeutics, Inc.
(ZVSA) is the lower-risk stock at 0. 29β versus Aldeyra Therapeutics, Inc. 's 1. 36β — meaning ALDX is approximately 367% more volatile than ZVSA relative to the S&P 500.
04Which is growing faster — ZVSA or ALDX?
On earnings-per-share growth, the picture is similar: ZyVersa Therapeutics, Inc.
grew EPS 50. 7% year-over-year, compared to 40. 4% for Aldeyra Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ZVSA or ALDX?
ZyVersa Therapeutics, Inc.
(ZVSA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Aldeyra Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZVSA leads at 0. 0% versus 0. 0% for ALDX. At the gross margin level — before operating expenses — ZVSA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ZVSA or ALDX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ZVSA or ALDX better for a retirement portfolio?
For long-horizon retirement investors, ZyVersa Therapeutics, Inc.
(ZVSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29)). Both have compounded well over 10 years (ZVSA: -100. 0%, ALDX: -69. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ZVSA and ALDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.